Combination therapy with tocilizumab and dexamethasone cost-effectively reduces Coronavirus disease 2019 mortality

Abstract

Abstract Recent randomized trials suggest that interleukin-6 inhibitors like tocilizumab have mortality benefit for patients with severe coronavirus disease-2019. We employed a decision tree to investigate their cost-effectiveness and found that tocilizumab is cost-effective with an estimated incremental cost-effectiveness ratio of $16520 per quality-adjusted life year gained (95% credible interval 10760-51530).